BioSpace News Archive

Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced it has raised $25 million in a Series C financing.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces interim clinical trial results from the company’s Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment for Ewing sarcoma and FET-rearranged sarcomas.

Outlook Therapeutics, Inc. announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will participate in a panel discussion titled, “Take A Look At What’s In Store For Wet AMD & Related Diabetic Eye Diseases,” at the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference on Thursday, December 8, 2022 at 2:45 PM ET.

Orchard Therapeutics, a global gene therapy leader, announced its marketing authorization application for Libmeldy® has been accepted for evaluation by the Swiss Agency for Therapeutic Products for the potential treatment of eligible patients with early-onset metachromatic leukodystrophy.

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended September 30, 2022 and provided an update on the Company’s business developments.

An Extraordinary General Meeting (the “EGM”) of Nordic Nanovector ASA (the “Company”) (OSE: NANOV) was held today on 1 December 2022 in Oslo, Norway.

Kintor Pharmaceutical Limited announced results of phase II clinical trial of pyrilutamide, a potential first-in-class topical drug developed by the company, in China for the treatment of adult female androgeneticalopecia.

Eagle Pharmaceuticals, Inc. today announced that the following distinguished Key Opinion Leaders will be featured at the Company’s Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace, at 8:00am ET.